Access
This article is part of Nature's premium content.
Published online 12 December 2007 | Nature 450, 935 (2007) | doi:10.1038/450935a
News in Brief: Business
Euro tie-up
Swiss drug giant Novartis has extended its partnership with MorphoSys, a German biotechnology firm, saying it will pay at least US$600 million over 10 years as the price of working with the smaller company to help it discover and develop antibody-based medicines. If Munich-based MorphoSys meets milestones for clinical development and market approval, the payments could exceed $1 billion, the companies said on 2 December.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email redesign@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.